These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 27371107)

  • 21. B cells in SLE: different biological drugs for different pathogenic mechanisms.
    Diamanti AP; Rosado MM; Carsetti R; Valesini G
    Autoimmun Rev; 2007 Dec; 7(2):143-8. PubMed ID: 18035325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-based therapies for systemic lupus erythematosus.
    Liao J; Chang C; Wu H; Lu Q
    Autoimmun Rev; 2015 Jan; 14(1):43-8. PubMed ID: 25308529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
    Wallace DJ; Linker-Israeli M; Metzger AL; Stecher VJ
    Lupus; 1993 Feb; 2 Suppl 1():S13-5. PubMed ID: 8485565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
    Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on emerging drug therapies for systemic lupus erythematosus.
    Mok CC
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):53-70. PubMed ID: 20148712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.
    Mease PJ; Ginzler EM; Gluck OS; Schiff M; Goldman A; Greenwald M; Cohen S; Egan R; Quarles BJ; Schwartz KE
    J Rheumatol; 2005 Apr; 32(4):616-21. PubMed ID: 15801015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hydroxychloroquine for autoimmune diseases].
    Danza Á; Graña D; Goñi M; Vargas A; Ruiz-Irastorza G
    Rev Med Chil; 2016 Feb; 144(2):232-40. PubMed ID: 27092678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic lupus erythematosus--2005 annus mirabilis?
    Isenberg D; Rahman A
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):145-52. PubMed ID: 16932674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.
    Mok CC
    Expert Rev Clin Immunol; 2017 Jan; 13(1):35-41. PubMed ID: 27417340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].
    Ampélas JF; Wattiaux MJ; Van Amerongen AP
    Encephale; 2001; 27(6):588-99. PubMed ID: 11865567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB; Morand EF; Mackay F
    Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
    Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis.
    Gatto M; Saccon F; Zen M; Bettio S; Iaccarino L; Punzi L; Doria A
    J Autoimmun; 2016 Nov; 74():94-105. PubMed ID: 27373904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history.
    Fanouriakis A; Mastorodemos V; Pamfil C; Papadaki E; Sidiropoulos P; Plaitakis A; Amoiridis G; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2014 Jun; 43(6):751-8. PubMed ID: 24332007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Tsakonas E; Joseph L; Esdaile JM; Choquette D; Senécal JL; Cividino A; Danoff D; Osterland CK; Yeadon C; Smith CD
    Lupus; 1998; 7(2):80-5. PubMed ID: 9541091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prasterone.
    Kocis P
    Am J Health Syst Pharm; 2006 Nov; 63(22):2201-10. PubMed ID: 17090740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BK viruria and viremia in children with systemic lupus erythematosus.
    Gupta N; Nguyen CQ; Modica RF; Elder ME; Garin EH
    Pediatr Rheumatol Online J; 2017 Apr; 15(1):21. PubMed ID: 28399927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
    Sthoeger Z; Sharabi A; Mozes E
    J Autoimmun; 2014 Nov; 54():60-71. PubMed ID: 24958634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.